Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.4 INR -1.54% Market Closed
Market Cap: 484.9m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Relative Value

526139 doesn't have a meaningful market cap.

The Relative Value of one TRABI stock under the Base Case scenario is 0.28 INR. Compared to the current market price of 6.4 INR, Transgene Biotek Ltd is Overvalued by 96%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TRABI Relative Value
Base Case
0.28 INR
Overvaluation 96%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
9
Median 3Y
296.2
Median 5Y
258.7
Industry
7.7
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3
Industry
22.7
vs History
12
vs Industry
100
Median 3Y
5 474.3
Median 5Y
271.3
Industry
21.6
vs History
12
vs Industry
0
Median 3Y
265.3
Median 5Y
-623.5
Industry
25.2
vs History
7
vs Industry
13
Median 3Y
2
Median 5Y
1.6
Industry
2.5
vs History
41
vs Industry
7
Median 3Y
396
Median 5Y
318.3
Industry
7.7
vs History
26
vs Industry
4
Median 3Y
301.2
Median 5Y
301.2
Industry
9
vs History
vs Industry
1
Median 3Y
-68.8
Median 5Y
-63.2
Industry
4.2
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-4.3
Industry
4.1
vs History
12
vs Industry
100
Median 3Y
7 868.7
Median 5Y
392.2
Industry
5.7
vs History
12
vs Industry
0
Median 3Y
390.3
Median 5Y
257.6
Industry
3.6
vs History
7
vs Industry
64
Median 3Y
0.3
Median 5Y
0.3
Industry
4.6

Multiples Across Competitors

TRABI Competitors Multiples
Transgene Biotek Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Transgene Biotek Ltd
BSE:526139
484.9m INR 263.3 -149.4 -68.8 -62.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 10.9 -242.3 24.1 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.9 17.5 15.9 17.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.8B EUR 18.7 -131 -105.5 -76.9
P/E Multiple
Earnings Growth
IN
Transgene Biotek Ltd
BSE:526139
Average P/E: 208.2
Negative Multiple: -149.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A
EV/EBITDA Multiple
EBITDA Growth
IN
Transgene Biotek Ltd
BSE:526139
Average EV/EBITDA: 17.2
Negative Multiple: -68.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A
EV/EBIT Multiple
EBIT Growth
IN
Transgene Biotek Ltd
BSE:526139
Average EV/EBIT: 22.5
Negative Multiple: -62.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

See Also

Discover More
Back to Top